FibroGen Inc. Daily Stock Analysis

Daily Stock Analysis, FGEN, FibroGen Inc, priceseries

FibroGen Inc. Daily Stock Analysis
Stock Information
Open
12.86
Close
12.69
High
13.35
Low
12.69
Previous Close
12.98
Daily Price Gain
-0.29
YTD High
16.91
YTD High Date
Feb 9, 2022
YTD Low
12.69
YTD Low Date
Mar 7, 2022
YTD Price Change
-2.13
YTD Gain
-14.37%
52 Week High
36.12
52 Week High Date
Apr 1, 2021
52 Week Low
9.88
52 Week Low Date
Oct 4, 2021
52 Week Price Change
-20.68
52 Week Gain
-61.97%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 13. 2017
25.25
May 5. 2017
27.51
15 Trading Days
8.94%
Link
LONG
Jun 20. 2017
30.15
Jul 13. 2017
32.25
16 Trading Days
6.97%
Link
LONG
Aug 28. 2017
43.50
Sep 22. 2017
51.11
18 Trading Days
17.50%
Link
LONG
Dec 20. 2017
44.55
Jan 4. 2018
48.00
9 Trading Days
7.74%
Link
LONG
Jan 22. 2018
49.90
Feb 2. 2018
56.74
9 Trading Days
13.71%
Link
LONG
May 30. 2018
52.70
Jun 26. 2018
61.83
19 Trading Days
17.32%
Link
LONG
Jan 4. 2019
45.36
Feb 20. 2019
56.29
31 Trading Days
24.09%
Link
LONG
Jun 7. 2019
38.70
Jun 25. 2019
42.01
12 Trading Days
8.55%
Link
LONG
Nov 19. 2019
37.65
Dec 18. 2019
46.63
20 Trading Days
23.85%
Link
LONG
Jun 12. 2020
38.16
Jun 26. 2020
40.76
10 Trading Days
6.81%
Link
LONG
Sep 2. 2020
45.37
Sep 3. 2020
48.47
1 Trading Days
6.82%
Link
LONG
Jan 14. 2021
43.06
Feb 17. 2021
51.61
22 Trading Days
19.85%
Link
LONG
Jun 7. 2021
22.90
Jun 29. 2021
27.30
16 Trading Days
19.21%
Link
LONG
Nov 30. 2021
12.51
Dec 13. 2021
13.49
9 Trading Days
7.82%
Link
Company Information
Stock Symbol
FGEN
Exchange
NasdaqGS
Company URL
http://www.fibrogen.com
Company Phone
415-978-1200
CEO
Thomas Byron Neff
Headquarters
California
Business Address
409 ILLINOIS STREET, SAN FRANCISCO, CA 94158
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000921299
About

FibroGen, Inc. operates as a research-based biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat unmet medical needs. It focuses on fibrosis and hypoxia-induced factor biology to generate programs targeting therapeutic areas. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.

Description

FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the United States. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading